Pfizer's Respiratory Syncytial Virus Vaccine Maintains Staying Power In Older Adults Through 2nd RSV season, Study Finds
Portfolio Pulse from Vandana Singh
Pfizer Inc (NYSE:PFE) announced that its Abrysvo vaccine for respiratory syncytial virus (RSV) in adults 60 and older maintained efficacy through a second RSV season, according to Phase 3 trial data. The vaccine showed 77.8% efficacy against severe RSV after the second season, with overall efficacy across both seasons at 81.5%. No new adverse events were reported in the second season. Abrysvo, approved by the FDA for preventing infection in infants, generated $890 million in sales in fiscal year 2023. PFE shares dropped 1.07% to $26.76.
February 29, 2024 | 7:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pfizer's Abrysvo RSV vaccine maintains efficacy in older adults through a second season, with no new adverse events reported. FY2023 sales reached $890 million. Shares fell 1.07% to $26.76.
The sustained efficacy and safety of Pfizer's Abrysvo vaccine through a second RSV season is positive news, indicating the vaccine's durability and potential for continued revenue generation. However, the slight drop in share price suggests a mixed market reaction, possibly due to broader market conditions or expectations of even more robust sales figures. The significant sales figures for Abrysvo in fiscal year 2023 underscore its commercial success and potential for future growth.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100